FRESENIUS SE+CO.KGAA O.N.
FRESENIUS SE+CO.KGAA O.N./ DE0005785604 /
FRE
2025-01-02 10:58:54 PM
|
Chg.
-0.130
|
Volume |
Bid10:58:54 PM |
Ask10:58:54 PM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
33.290EUR
|
-0.39%
|
- Turnover: - |
33.290Bid Size: - |
33.440Ask Size: - |
18.75 bill.EUR |
- |
- |
Business description
Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care.
Management board & Supervisory board
CEO |
Michael Sen |
Management board |
Sara Hennicken, Pierluigi Antonelli , Robert Möller, Michael Moser |
Supervisory board |
Wolfgang Kirsch, Prof. Dr. D. Michael Albrecht, Bernd Behlert , Michael Diekmann , Grit Genster , Frauke Lehmann , Prof. Dr. med. Iris Löw-Friedrich , Susanne Zeidler , Dr. Christoph Zindel , Holger Michel, Harald Steer, Oscar Romero de Paco |
Company data
Name: |
Fresenius SE & Co. KGaA |
Address: |
Else-Kröner-Straße 1,D-61352 Bad Homburg |
Phone: |
+49-6172-608-0 |
Fax: |
- |
E-mail: |
pr-fre@fresenius.com
|
Internet: |
www.fresenius.de |
Industry: |
Healthcare |
Sector: |
Medical Products |
Sub sector: |
Advanced Medical Devices |
End of financial year: |
12-31 |
Free Float: |
56.49% |
IPO date: |
1986-12-18 |
Investor relations
Name: |
Markus Georgi |
IR phone: |
+49-6172-608-2485 |
IR Fax: |
+49-6172-608-2488 |
IR e-mail: |
ir-fre@fresenius.com
|
Company calendar
CW 9 | 2025-02-26
Annual Report
|
CW 19 | 2025-05-07
Interim Report 1st Quarter/3 Months
|
CW 21 | 2025-05-23
General Shareholder Meeting
|
CW 32 | 2025-08-06
Interim Report 2nd Quarter/6 Months
|
CW 45 | 2025-11-05
Interim Report 3rd Quarter/9 Months
|